Compare Procter & Gamble Health with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs TORRENT PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH TORRENT PHARMA PROCTER & GAMBLE HEALTH/
TORRENT PHARMA
 
P/E (TTM) x 52.3 56.7 92.3% View Chart
P/BV x 4.7 6.0 79.0% View Chart
Dividend Yield % 10.0 0.9 1,171.0%  

Financials

 PROCTER & GAMBLE HEALTH   TORRENT PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
TORRENT PHARMA
Mar-18
PROCTER & GAMBLE HEALTH/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3,5491,550 229.0%   
Low Rs1,3011,144 113.8%   
Sales per share (Unadj.) Rs511.4354.7 144.2%  
Earnings per share (Unadj.) Rs61.340.1 152.9%  
Cash flow per share (Unadj.) Rs74.064.2 115.2%  
Dividends per share (Unadj.) Rs440.0014.00 3,142.9%  
Dividend yield (eoy) %18.11.0 1,745.3%  
Book value per share (Unadj.) Rs927.8273.1 339.7%  
Shares outstanding (eoy) m16.60169.22 9.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.8 124.9%   
Avg P/E ratio x39.633.6 117.7%  
P/CF ratio (eoy) x32.821.0 156.3%  
Price / Book Value ratio x2.64.9 53.0%  
Dividend payout %717.934.9 2,055.0%   
Avg Mkt Cap Rs m40,257227,897 17.7%   
No. of employees `0001.114.7 7.7%   
Total wages/salary Rs m1,31311,353 11.6%   
Avg. sales/employee Rs Th7,486.74,083.0 183.4%   
Avg. wages/employee Rs Th1,157.6772.3 149.9%   
Avg. net profit/employee Rs Th897.2461.3 194.5%   
INCOME DATA
Net Sales Rs m8,49060,021 14.1%  
Other income Rs m2442,988 8.2%   
Total revenues Rs m8,73463,009 13.9%   
Gross profit Rs m1,48213,493 11.0%  
Depreciation Rs m2114,086 5.2%   
Interest Rs m03,085 0.0%   
Profit before tax Rs m1,5149,310 16.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5632,529 22.2%   
Profit after tax Rs m1,0176,781 15.0%  
Gross profit margin %17.522.5 77.6%  
Effective tax rate %37.127.2 136.8%   
Net profit margin %12.011.3 106.1%  
BALANCE SHEET DATA
Current assets Rs m15,34352,623 29.2%   
Current liabilities Rs m1,96052,022 3.8%   
Net working cap to sales %157.61.0 15,729.3%  
Current ratio x7.81.0 773.8%  
Inventory Days Days49120 40.8%  
Debtors Days Days2876 37.3%  
Net fixed assets Rs m1,20985,016 1.4%   
Share capital Rs m166846 19.6%   
"Free" reserves Rs m15,23545,376 33.6%   
Net worth Rs m15,40146,222 33.3%   
Long term debt Rs m041,115 0.0%   
Total assets Rs m17,595142,432 12.4%  
Interest coverage xNM4.0-  
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.50.4 114.5%   
Return on assets %5.86.9 83.5%  
Return on equity %6.614.7 45.0%  
Return on capital %10.314.2 72.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63614,580 11.2%   
Fx outflow Rs m4,3683,600 121.3%   
Net fx Rs m-2,73210,980 -24.9%   
CASH FLOW
From Operations Rs m-1,3048,942 -14.6%  
From Investments Rs m12,697-47,070 -27.0%  
From Financial Activity Rs m-30134,174 -0.9%  
Net Cashflow Rs m11,093-3,655 -303.5%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 7.0 259.3%  
FIIs % 1.0 12.6 7.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 8.8 330.7%  
Shareholders   28,591 26,511 107.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   SANOFI INDIA  NATCO PHARMA  BIOCON   PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 93 Points Higher; Oil & Gas and Realty Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the oil & gas sector.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Oct 16, 2019 03:37 PM

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS